SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? : Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications
AIMS: Metformin has hitherto not been proven superior to other type 2 diabetes (T2D) medications for the prevention of organ complications. The aim of this study is to report baseline data and blinded interim analyses in the register-based randomised clinical trial (RRCT) SMARTEST, which compares metformin and the SGLT2 inhibitor dapagliflozin in early T2D. We also present learnings from the novel
